Isadora Mamede MD

🇧🇷 First-gen MD @ufsjbr '25 | Interested in #Oncology | Physician-scientist aspirant

[Isadora Mamede MD @theisamamede]

Key finding: chemoimmunotherapy improves pathological response, and nivolumab + chemotherapy showed the most consistent pCR benefit, though no clear survival advantage has emerged yet.

[Isadora Mamede MD @theisamamede]

Excited to share our new publication in Clinical Lung Cancer!

We performed a network meta-analysis on resectable NSCLC with PD-L1 <1%, including 8 RCTs and 3,387 patients.

🔗 Read here:
https://t.co/a4XLp53Oks

#LungCancer #NSCLC #Immunotherapy #OncologyResearch #medtwitter

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Isadora Mamede MD @theisamamede]

Nunca fiquei tão feliz de receber um e-mail igual hoje com o do setor de assuntos internacionais da UFSJ falando que vão descobrir quem tem acesso ao MyIntealth e se não, irão contatar o ECFMG para recuperar o acesso. Tem 3 meses que estou pedindo para fazerem isso.

[Isadora Mamede MD @theisamamede]

Happy to have presented our work at #ASCOGU26. Thank you to all the team and their hard work.

[Isadora Mamede MD @theisamamede]

Quer construir uma carreira médica internacional e ver seu nome no PubMed? 🌍📚

🚨 Lista de espera aberta — Meta-Analysis Academy (mar/2026)
🔗 https://t.co/tnCbkKLOsf

Revisões sistemáticas e meta-análises com Dr. Rhanderson Cardoso (Harvard | Johns Hopkins).

[Isadora Mamede MD @theisamamede]

Happy to share that our abstract got accepted to ASCO GU 2026.
This wouldn't be possible without the support of our mentors and the @metaacademy_ofc team.

[Isadora Mamede MD @theisamamede]

@metaacademy_ofc It wouldn't be possible without the support of the whole meta analysis academy team!

[Isadora Mamede MD @theisamamede]

🚀 Our new Bayesian network meta-analysis on treatments for LACC is out now!
We compare 11 strategies across 47 RCTs — reaffirming CCRT as the backbone while highlighting promising ICI and IC approaches.
@metaacademy_ofc

🔗Read here: https://t.co/vWTXnyx0G5

[Isadora Mamede MD @theisamamede]

@AitchT7 Congratulations! Highest score I've ever seen.

[Isadora Mamede MD @theisamamede]

I am pleased to share our meta-analysis on adjuvant ICI in early stage NSCLC. Co-lead by @CarlosStecca.
We observed DFS benefits but no OS advantages.

Read here:
https://t.co/ncYmPYfO4K

Thanks @metaacademy_ofc for connecting me with this team.
#MedTwitter #OncTwitter #Research

[Kevin Croce MD, PhD @kevinjamescroce]

We have two spots available for the 2026 Mass General Brigham Integrated Complex and CTO PCI fellowship. Applicants- please forward CV, personal statement, and 2 recommendation letters to Melissa Gayle ([email protected]).
https://t.co/hRHHsrekyM

[Isadora Mamede MD @theisamamede]

Proud to share our meta-analysis in AJEM! @carvalhalgiulia
It shows that early vasopressin plus norepinephrine in septic shock is linked to a shorter hospital stay, though mortality remains unchanged — Timing matters.
https://t.co/iLgL36qjJt

#MedTwitter #CriticalCare

[Harlan Krumholz @hmkyale]

In this Editor’s Page, I outline why we believe authors can use AI tools to improve scientific writing—if they fully own what they submit.
At JACC, we won’t stigmatize responsible use of AI. But we will insist on accountability.
https://t.co/yIjXsct4mS
@JACCJournals @YaleMed

[Isadora Mamede MD @theisamamede]

After over 3yrs, we published our study about the development and reliability of a mobile app for craniofacial assesment in OSA. It's a promising alternative to standard approaches in resource limited regions.
📚 Read it
https://t.co/MdFQG0TLxJ

#sleepmedicine #OSA #research

[Tom Powles @tompowles1]

Big news in bladder cancer. R3 (n=480) of Disitimab Vedotin(HER2ADC) + Tori (PD1) vs chemo, hitting PFS + OS in 1st line irrespective of HER2 . “This reshapes the global treatment landscape of urothelial carcinoma with the Chinese regimen,”said Dr. Jun Guo https://t.co/yz7GePkrOP

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🌟📢 @ASCO #GU25 |
Abstract #664
🔬 EV-302 confirms superior efficacy of EV+P vs chemo in 1L la/mUC!🌟
@tompowles1 @shilpaonc
📊 Key Findings (N=886, Median FU: 29.1 months)
✅ Median OS: 33.8 vs. 15.9 months (HR: 0.51, 95% CI: 0.43-0.61)
✅ PFS (BICR): 12.5 vs. 6.3 months (HR: 0.48, 95% CI: 0.41-0.57)
✅ Confirmed ORR: 67.5% vs. 44.2%
✅ cCR Rates: 30.4% vs. 14.5%
✅ Grade ≥3 TRAEs lower with EV+P (57.3% vs. 69.5%)

📌 Clinical Takeaway:
🔹 EV+P remains the clear SOC for 1L la/mUC with durable efficacy & manageable safety.

👥 @ASCO @OncoAlert @UroToday @GUOncologyNow @gu_onc
@montypal
@neerajaiims
@Uromigos
@urotoday
@OncLive
@fredhutch
@nicoleflemingmd
@acampsmalea
@BiagioRicciutMD
@yekeduz_emre
@HHorinouchi
@FadiHaddad_MD
@Dr_Ivanoncologo
@Abdallah81MD
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@bavilima
@realbowtiedoc
@Erman_Akkus
@Lucarecco
@GaiaGriguolo
@JankovicK
#BladderCancer #EV302 #Immunotherapy

[Comron Saifi MD @TheSpineSurgeon]

Accepting applications for a funded spine surgery research fellowship at @HMethodistMD

Our research focuses on advancing clinical practice and improving patient outcomes. Studies include prospective RCTs, motion analysis, spinal oncology, & more.

Apply: https://t.co/HCW8u5GVnX

[Isadora Mamede MD @theisamamede]

Non-US IMGs be like:

[L 🇨🇦 @Ann_Hedonia1]

I just need to get through the next 30 or 40 years and things should settle down

[Isadora Mamede MD @theisamamede]

Our recently published meta-analysis shows that sublobar resection is a viable surgical option in Stage IA NSCLC. #MedTwitter #lungcancer #surgery
📰Read more:
https://t.co/IlsL60W99i